These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38409713)

  • 1. Antipsychotics in Alzheimer's Disease: Current Status and Therapeutic Alternatives.
    Maziero MP; Rocha NP; Teixeira AL
    Curr Alzheimer Res; 2023; 20(10):682-691. PubMed ID: 38409713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
    Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.
    Creese B; Da Silva MV; Johar I; Ballard C
    Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
    Kirbach S; Simpson K; Nietert PJ; Mintzer J
    Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Nakajima S; Mimura M; Shigeta M
    J Alzheimers Dis; 2018; 66(1):139-148. PubMed ID: 30248052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole in the treatment of Alzheimer's disease.
    De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
    Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.
    Oguma T; Jino K
    Chem Pharm Bull (Tokyo); 2024; 72(7):610-617. PubMed ID: 38945937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease.
    Wolinsky D; Drake K; Bostwick J
    Curr Psychiatry Rep; 2018 Oct; 20(12):117. PubMed ID: 30367272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosis and antipsychotic medications in Alzheimer's disease: clinical management and research perspectives.
    Sultzer DL
    Dement Geriatr Cogn Disord; 2004; 17(1-2):78-90. PubMed ID: 14566100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.